Dosing and Safety

The only branded ICS* with a once-daily dosing option FDA-approved for patients 12 months to 8 years of age

PULMICORT RESPULES has a well-established safety profile.²³ And, with once-daily dosing options, PULMICORT RESPULES can be administered once-or-twice-daily, in varying doses, to help meet your patients’ needs.²³

PULMICORT RESPULES was effective dosed once-or-twice-daily. However, when all measures were considered together, the evidence was stronger for twice-daily dosing.^†

In this section

Flexible Dosing Options
Once-or-twice daily options to help meet your patients’ needs.²³

Well-Established Safety Profile
Approved for patients 12 months to 8 years of age.^1,23

Footnotes

*Inhaled corticosteroid
^†Verispan patient-level data May 2003-December 2005

Enlarge Text:

Print:

Educational resources for families in your care.

Links to learn about other asthma treatment options for patients:

Indication

PULMICORT RESPULES is indicated for the maintenance treatment of asthma and as prophylactic therapy in children ages 12 months to 8 years.

PULMICORT RESPULES is not a bronchodilator and is NOT indicated for the relief of acute bronchospasm.

Important Safety Information

Inhaled corticosteroids may cause a reduction in growth velocity. The long-term effect on final adult height is unknown.

PULMICORT RESPULES, like other inhaled corticosteroids, may impact the hypothalamic-pituitary-adrenal axis, especially in susceptible individuals, in young children, and in patients given high doses for prolonged periods.

Particular care is needed for patients who are transferred from systemically active corticosteroids to less systemically available corticosteroids, because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids (see WARNINGS in full Prescribing Information).

Patients taking immunosuppressant doses of corticosteroids should avoid exposure to infections such as chicken pox and measles.

Common adverse events reported in clinical trials, regardless of relationship to treatment, included respiratory infection, rhinitis, coughing, otitis media, viral infection, gastroenteritis, ear infection, oral thrush/candidiasis, and epistaxis.

Please see accompanying full Prescribing Information (PDF).

Site Map | References | Contact Us